Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Liquidia Technologies. The associated price target remains the same with $35.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein has given his Buy rating due to a combination of factors that highlight the strong initial performance of Liquidia Technologies’ newly launched product, Yutrepia. Within just 11 weeks of its approval, Yutrepia has seen rapid adoption, with over 350 physicians prescribing it and more than 550 patients starting treatment. This uptake is attributed to increased brand awareness and improvements in the payer landscape, which have facilitated access to the medication.
Fein’s positive outlook is further reinforced by the company’s strategic deployment of patient services, such as co-pay support and free drug vouchers, which have supported the product’s market entry. Additionally, Yutrepia’s unique PRINT technology and dry powder formulation offer clinical advantages, such as deep lung deposition and flexible dosing, distinguishing it from competitors. The company’s plans to present detailed data at upcoming conferences and conduct further studies underscore its commitment to establishing Yutrepia as a leading treatment option, contributing to Fein’s confidence in the stock’s potential growth.
In another report released today, Raymond James also maintained a Buy rating on the stock with a $41.00 price target.